Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BRCA1 and BRCA2 alterations are associated with an increased risk of developing breast carcinoma. The authors hypothesized that the progression of breast neoplasia may differ between patients with hereditary disease and patients with nonhereditary disease and that this difference in progression may be visualized by studying the prevalence of precursor lesions and neoplastic lesions. METHODS: The authors developed two case cohorts of high‐risk patients with a strong family history of breast carcinoma who underwent prophylactic mastectomy. The first cohort was comprised of women who underwent therapeutic mastectomy and contralateral prophylactic mastectomy, and the second cohort was comprised of women who underwent bilateral prophylactic mastectomy. Patients without a family history of breast carcinoma who underwent unilateral or bilateral prophylactic mastectomy were selected as a control group. DNA from peripheral blood leukocytes was screened for BRCA1 and BRCA2 mutations. The available pathologic materials were reviewed independently by two pathologists, and all neoplastic and precursor lesions were identified and classified. Proliferation activity was assessed using MIB‐1 immunohistochemistry on all available lesions from the unilateral mastectomy cohort. RESULTS: The 28 women from the unilateral cohort with deleterious BRCA1/2 mutations had a lower prevalence of proliferative fibrocystic changes (PFC) (7%) compared with their matched control group (25%) (P = 0.075) and with patients who had a family history but no BRCA1/2 mutation (22–33%). None of the 11 deleterious mutation carriers from the bilateral cohort (0%) had PFC compared with 36% of women in the matched control group (P = 0.03). There was no major difference in the prevalence of other precursor lesions (including in situ carcinoma) in either cohort. Invasive carcinomas from the deleterious mutation carriers in the unilateral cohort were of higher grade compared with the control group (P = 0.003) and patients without a mutation (P < 0.0001) but were of similar grade compared with carriers of unclassified variant BRCA1/2 alterations (P = 0.20). Neoplastic lesions from the deleterious mutation carriers in the unilateral cohort had higher MIB‐1 proliferation indices compared with other patients with and without a family history of breast carcinoma. CONCLUSIONS: The current data suggest that the progression rate of breast neoplasia is accelerated in women who carry BRCA1/2 deleterious mutations compared with other patients who have breast carcinoma with or without a family history. This increased progression rate should be taken into account when considering the surveillance of asymptomatic women. Cancer 2003;97:1–11. © 2003 American Cancer Society. DOI 10.1002/cncr.11048
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Self-citationBRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648 · cited 1×
“25 Nuclear pleomorphism Score 1 0 5 (11) 0 5 (25) 16 (31) 53 (34) Score 2 6 (35) 27 (60) 3 (50) 12 (60) 29 (56) 83 (53) Score 3 11 (65) 13 (29) 3 (50) 3 (15) 7 (13) 21 (13) P value 0.”
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Research works printed but not linked: 36
- 10.4065/72.1.54 · DOI
- 10.1056/NEJM198705213162101 · DOI · Paper page
- 10.1677/erc.0.0080047 · DOI · Paper page
- 10.1007/s001090050128 · DOI · Paper page
- 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5 · DOI · Paper page
- 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
- 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S · DOI
- 10.1016/S0046-8177(98)90427-0 · DOI
- 10.1056/NEJM199901143400201 · DOI · Paper page
- 10.1200/JCO.2001.19.19.3938 · DOI · Paper page
- 10.1200/JCO.1998.16.7.2417 · DOI · Paper page
- Elston CW, 1998, The breast
- Page DL, 1987, Diagnostic histopathology of the breast
- 10.1002/(SICI)1097-0142(19971101)80:9<1798::AID-CNCR15>3.0.CO;2-0 · doi:10.1002/(sici)1097-0142(19971101)80:9<1798::aid-cncr15>3.0.co;2-0
- 10.1111/j.1365-2559.1991.tb00229.x · DOI · Paper page
- 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N · DOI · Paper page
- 10.1126/science.2270486 · DOI
- 10.1093/jnci/50.5.1111 · doi:10.1093/jnci/50.5.1111
- 10.1093/jnci/90.9.697 · DOI · Paper page
- 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I · doi:10.1002/1097-0142(19930615)71:12<3896::aid-cncr2820711217>3.0.co;2-i
- Kamel OW, 1992, In situ proliferative epithelial lesions of the breast, Pathology., 1, 65
- 10.1001/jama.1992.03480070057030 · DOI · Paper page
- Fitzgibbons PL, 1998, Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists, Arch Pathol Lab Med., 122, 1053
- 10.1016/0046-8177(93)90243-A · doi:10.1016/0046-8177(93)90243-a
- 10.1093/oxfordjournals.aje.a112413 · DOI
- 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M · doi:10.1002/1097-0142(19871201)60:11<2751::aid-cncr2820601127>3.0.co;2-m
- 10.1093/jnci/90.15.1138 · DOI · Paper page
- 10.1101/gad.879201 · DOI · Paper page
- 10.1038/sj.onc.1204512 · DOI
- 10.1046/j.1365-2559.1997.5720795.x · doi:10.1046/j.1365-2559.1997.5720795.x
- 10.1186/bcr12 · DOI
- 10.1016/S1357-4310(98)01262-3 · DOI
- 10.1038/ng0495-444 · DOI · Paper page
- 10.1056/NEJM200102223440801 · DOI · Paper page
- 10.1001/jama.1921.02630320038011 · doi:10.1001/jama.1921.02630320038011
- 10.1002/cncr.10949 · DOI · Paper page
Cited by
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
“On the other hand, BRCA2 mutation carriers present tumours with pathological features similar to sporadic cases [10–16].”
BackgroundKirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102
Metadata
- Authors
- Adem, C., Reynolds, C., Soderberg, C. L., Slezak, J. M., McDonnell, S. K., Sebo, T. J., Schaid, D. J., Myers, J. L., Sellers, T. A., Hartmann, L. C., & Jenkins, R. B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-12-18
- Volume
- 97
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2023887123
- Cited by
- 85
- References
- 4
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. https://app.cochat.ai/papers/10.1002/cncr.11048
- The paper
- Adem, C., Reynolds, C., Soderberg, C. L., Slezak, J. M., McDonnell, S. K., Sebo, T. J., Schaid, D. J., Myers, J. L., Sellers, T. A., Hartmann, L. C., & Jenkins, R. B. (2003). Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer. https://doi.org/10.1002/cncr.11048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.